Share:
NEW YORK, May 14, 2021 (GLOBE NEWSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ( Acadia or the Company )(NASDAQ:ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acadia securities between June 15, 2020 and April 4, 2021, both dates inclusive (the Class Period ), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kadmon Holdings, Inc., of Class Action Lawsuit and Upcoming Deadline – KDMN
May 14, 2021 22:42 ET | Source: Pomerantz LLP Pomerantz LLP New York, New York, UNITED STATES
NEW YORK, May 14, 2021 (GLOBE NEWSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Kadmon Holdings, Inc. (“Kadmon” or the “Company”) (NASDAQ: KDMN) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 21-cv-01797, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Kadmon securities between October 1, 2020 and March 10, 2021, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws a
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in LifeMD, Inc. f/k/a Conversion Labs, Inc. of Class Action Lawsuit and Upcoming Deadline – LFMD
Home / Top News / SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in LifeMD, Inc. f/k/a Conversion Labs, Inc. of Class Action Lawsuit and Upcoming Deadline – LFMD
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in LifeMD, Inc. f/k/a Conversion Labs, Inc. of Class Action Lawsuit and Upcoming Deadline – LFMD
NEW YORK, May 14, 2021 (GLOBE NEWSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. f/k/a Conversion Labs, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 21-cv-04004, is on behalf of a class consisting o
IP Attaché for Brazil
As one of two U.S. intellectual property (IP) attachés assigned to South America, David Kellis is the Rio de Janeiro-based principal officer on matters related to the protection and enforcement of IP rights within U.S. embassies and consulates throughout Argentina, Brazil, French Guiana, Guyana, Paraguay, Suriname, Uruguay, and Venezuela. His duties include advocating for the U.S. IP interests abroad by promoting high standards of IP protection and enforcement in the region; assisting U.S. companies; advising U.S. government officials on IP matters; educating foreign government officials, students, entrepreneurs, and business representatives on IP matters; and conducting public awareness programs.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline – FGEN
Home / Top News / SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline – FGEN
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline – FGEN
NEW YORK, May 14, 2021 (GLOBE NEWSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-03212, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired FibroGen secu